03 February 2017
IntegraGen today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.
Objectives of Fundraising
The funds received will permit IntegraGen to accelerate its development by (…) »
14 October 2016
IntegraGen today announced its sales for the first half 2016. Sales for IntegraGen’s business totaled € 2.8 million as of June 30, 2016, and increase of 10% compared to the first half of 2015.
Financials
Sales of € 2.8 million, a 10% increase vs. H1 2015 Operational result +14% (…) »10 October 2016
Data presented concludes that miR-31-3p expression is predictive of anti-EGFR therapy effect on objective response, depth of response, and early tumor shrinkage in patients with metastatic colorectal cancer enrolled in prospective, randomized FIRE-3 Trial.
07 July 2016
IntegraGen has announced its sales for the first half 2016. The company reported strong growth for its clinical research and microbiology genomics businesses and stability in its genomic services business for research activities with a significant increase in orders across all genomic activities.
29 June 2016
The Greater Paris University Hospitals (AP-HP) and IntegraGen announced today an agreement to develop a high-throughput sequencing platform (exome and whole genome) to be utilized for research projects and clinical research initiatives. This three-year research partnership aligns with a major objective of AH-HP’s 2015-2019 Strategic Plan related to (…) »
06 June 2016
IntegraGen presented positive clinical results on its miR-31-3p biomarker during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The data presented demonstrates that IntegraGen’s proprietary miR-31-3p biomarker is predictive for both survival and treatment response in patients receiving anti-EGFR therapy.
(…) »
08 April 2016
IntegraGen today announced its financial results for the year ended 31 December 2015.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on April 7, 2016.14 January 2016
IntegraGen reports its 2015 Revenues : Strong cash position; Robust development of activity on genomic platforms; Lower revenue for genomic services business.
02 December 2015
IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.
17 November 2015
Gustave Roussy and IntegraGen announced the achievement of one thousand genomic analyses utilizing their combined sequencing platform. The molecular profiles of cancer patients were analyzed as part of personalized medicine clinical trials being conducted at Gustave Roussy. The ability to deliver these results in less than three weeks (…) »
